Utilizing FAERS database (2004–2024; 17,670 IL-1 inhibitor-related AE reports), our analysis not only confirmed established drug-specific safety profiles—such as injection site reactions with anakinra and gastrointestinal/respiratory disorders with canakinumab—but also provided a systematic evaluation of IL-1 inhibitors safety as a whole class (alongside head-to-head comparisons among anakinra, canakinumab, rilonacept), identifying novel drug-specific AEs. The gene discussed is IL1B; the disease is respiratory system disorder.